JAZZ Collar Strategy
JAZZ (Jazz Pharmaceuticals plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ (Jazz Pharmaceuticals plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $14.58B, a trailing P/E of 487.62, a beta of 0.27 versus the broader market, a 52-week range of 103.6-235, average daily share volume of 1.0M, a public-listing history dating back to 2007, approximately 3K full-time employees. These structural characteristics shape how JAZZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.27 indicates JAZZ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 487.62 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a collar on JAZZ?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current JAZZ snapshot
As of May 15, 2026, spot at $228.38, ATM IV 32.20%, IV rank 11.60%, expected move 9.23%. The collar on JAZZ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on JAZZ specifically: IV regime affects collar pricing on both sides; compressed JAZZ IV at 32.20% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 9.23% (roughly $21.08 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JAZZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JAZZ should anchor to the underlying notional of $228.38 per share and to the trader's directional view on JAZZ stock.
JAZZ collar setup
The JAZZ collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JAZZ near $228.38, the first option leg uses a $240.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JAZZ chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JAZZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $228.38 | long |
| Sell 1 | Call | $240.00 | $4.75 |
| Buy 1 | Put | $220.00 | $5.25 |
JAZZ collar risk and reward
- Net Premium / Debit
- -$22,888.00
- Max Profit (per contract)
- $1,112.00
- Max Loss (per contract)
- -$888.00
- Breakeven(s)
- $228.88
- Risk / Reward Ratio
- 1.252
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
JAZZ collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on JAZZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$888.00 |
| $50.50 | -77.9% | -$888.00 |
| $101.00 | -55.8% | -$888.00 |
| $151.49 | -33.7% | -$888.00 |
| $201.99 | -11.6% | -$888.00 |
| $252.48 | +10.6% | +$1,112.00 |
| $302.98 | +32.7% | +$1,112.00 |
| $353.47 | +54.8% | +$1,112.00 |
| $403.97 | +76.9% | +$1,112.00 |
| $454.46 | +99.0% | +$1,112.00 |
When traders use collar on JAZZ
Collars on JAZZ hedge an existing long JAZZ stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
JAZZ thesis for this collar
The market-implied 1-standard-deviation range for JAZZ extends from approximately $207.30 on the downside to $249.46 on the upside. A JAZZ collar hedges an existing long JAZZ position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current JAZZ IV rank near 11.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JAZZ at 32.20%. As a Healthcare name, JAZZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JAZZ-specific events.
JAZZ collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JAZZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JAZZ alongside the broader basket even when JAZZ-specific fundamentals are unchanged. Always rebuild the position from current JAZZ chain quotes before placing a trade.
Frequently asked questions
- What is a collar on JAZZ?
- A collar on JAZZ is the collar strategy applied to JAZZ (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With JAZZ stock trading near $228.38, the strikes shown on this page are snapped to the nearest listed JAZZ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JAZZ collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the JAZZ collar priced from the end-of-day chain at a 30-day expiry (ATM IV 32.20%), the computed maximum profit is $1,112.00 per contract and the computed maximum loss is -$888.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JAZZ collar?
- The breakeven for the JAZZ collar priced on this page is roughly $228.88 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JAZZ market-implied 1-standard-deviation expected move is approximately 9.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on JAZZ?
- Collars on JAZZ hedge an existing long JAZZ stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current JAZZ implied volatility affect this collar?
- JAZZ ATM IV is at 32.20% with IV rank near 11.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.